Multiple sclerosis is a chronic inflammatory autoimmune disease of the central nervous system characterized by demyelination and axonal damage that result in disabling neurological deficits. Here the authors explain the rationale for the use of inhibitors of the Kv1.3 K+ channel in immune cells as a therapy for multiple sclerosis and other autoimmune disorders.
Archelos J, Storch M, Hartung H.2000. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol47:694–706.
3.
Bao J, Miao S, Kayser F, Kotliar AJ, Baker RK, Doss GA, and others. 2005. Potent Kv1.3 inhibitors from correolide—modification of the C18 position. Bioorg Med Chem Letts15:447–451.
4.
Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z.2004. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand109:390–392.
5.
Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel A, Gola M, and others. 2001. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol166:936–944.
6.
Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, and others. 2005. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol67:1369–1381.
7.
Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington MW, Bernard D, and others. 2001. Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A98:13942–13947.
8.
Ben-Nun A, Wekerle H, Cohen IR. 1981. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol11:195–199.
9.
Bernard CC, Leydon J, Mackay IR. 1976. T cell necessity in the pathogenesis of experimental autoimmune encephalomyelitis in mice. Eur J Immunol6:655–660.
10.
Bielekova B, Goodin B, Richert N, Cortese I, Kondo T, Afshar G, and others. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med6:1167–1175.
11.
Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, and others. 2004. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon b. Proc Natl Acad Sci U S A101:8705–8708.
12.
Bock J, Szabo I, Jekle A, Gulbins E.2002. Actinomycin D-induced apoptosis involves the potassium channel Kv1.3.Biochem Biophys Res Commun295:526–531.
13.
Booss J, Esiri MM, Tourtellotte WW, Mason DY. 1983. Immunohistological analysis of T lymphocytes subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci62:219–232.
14.
Bordey A, Spencer D.2003. Chemokine modulation of high-conductance Ca2+-sensitive K+ currents in microglia from human hippocampi. Eur J Neurosci18:2893–2898.
Burns J, Bartholomew B, Lobo S.1999. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann Neurol45:33–39.
17.
Cahalan MD, Chandy KG, DeCoursey TE, Gupta S.1985. A voltage-gated potassium channel in human T lymphocytes. J Physiol358:197–237.
18.
Cahalan MD, Wulff H, Chandy KG. 2001. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol21:235–252.
19.
Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S.1984. Voltage-gated potassium channels are required for human T lymphocyte activation. J Exp Med160:369–385.
20.
Chandy KG, DeCoursey TE, Fischbach M, Talal N, Cahalan MD, Gupta S.1986. Altered K+ channel expression in abnormal T lymphocytes from mice with the lpr gene mutation. Science233:1197–11200.
21.
Chittajallu R, Chen Y, Wang H, Yuan X, Ghiani CA, Heckman T, and others. 2002. Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle. Proc Natl Acad Sci U S A99:2350–2355.
22.
Conforti L, Petrovic M, Mohammad D, Lee S, Ma Q, Barone S, and others. 2003. Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation. J Immunol170:695–702.
23.
Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A, and others. 2004. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A101:11064–11069.
24.
Dalbeth N, Gundle R, Davies RJO, Lee YCG, McMichael AJ, Callan MFC. 2004. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol173:6418–6426.
25.
Davis FA, Stefoski D, Rush J.1990. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol27: 186–192.
26.
De Bleecker JL, Engel AG. 1995. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am J Pathol146:1178–1187.
27.
DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. 1984. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?Nature307:465–468.
28.
Decoursey TE, Chandy KG, Gupta S, Cahalan MD. 1987a. Mitogen induction of ion channels in murine T lymphocytes. J Gen Physiol89:405–420.
29.
Decoursey TE, Chandy KG, Gupta S, Cahalan MD. 1987b. Two types of potassium channels in murine T lymphocytes. J Gen Physiol89:379–404.
30.
DeCoursey TE, Kim SY, Silver MR, Quandt FN. 1996. Ion channel expression in PMA-differentiated human THP-1 macrophages. J Membr Biol152:141–157.
31.
Dolmetsch RE, Xu K, Lewis RS. 1998. Calcium oscillations increase the efficiency and specificity of gene expression. Nature392:933–936.
32.
Eder C.1998. Ion channels in microglia (brain macrophages). Am J Physiol Cell Physiol275:C327–C342.
33.
Ellis CN, Krueger GG. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med345:248–255.
34.
Fanger CM, Ghanshani S, Logsdon NJ, Rauer H, Kalman K, Zhou J, and others. 1999. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J Biol Chem274:5746–5754.
35.
Fasth A, Cao D, van Vollenhoven R, Trollmo C, Malmstrom V.2004. CD28nullCD4+ T cells—characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol60:199–208.
36.
Fiocco U, Rosada M, Cozzi L, Ortolani C, De Silvestro G, Ruffatti A, and others. 1993. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis52:272–277.
37.
Freedman BD, Fleischmann BK, Punt JA, Gaulton G, Hashimoto Y, Kotlikoff MI. 1995. Identification of Kv1.1 expression by murine CD4-CD8- thymocytes. J Biol Chem270:22406–22411.
38.
Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K.2000. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res292:519–521.
39.
Fukushima Y, Hagiwara S, Henkart M.1984. Potassium current in clonal cytotoxic T lymphocytes from the mouse. J Physiol351:645–656.
40.
Gallin EK. 1984. Calcium- and voltage-activated potassium channels in human macrophages. Biophys J46:821–825.
41.
Garcia de Tena J, Manzano L, Leal JC, San Antonio E, Sualdea V, Alvarez-Mon M.2004. Active Crohn’s disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J Clin Immunol24:185–196.
42.
Gessl A, Waldhausl W.1998. Elevated CD69 expression on naive peripheral blood T-cells in hyperthyroid Graves’ disease and autoimmune thyroiditis: discordant effect of methimazole on HLA-DR and CD69. Clin Immunol Immunopathol87:168–175.
43.
Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, and others. 2000. Up-regulation of the IKCa1 potassium channel during T-cell activation: molecular mechanism and functional consequences. J Biol Chem275:37137–37149.
44.
Gipson K, Bordey A.2002. Analysis of the K+ current profile of mature rat oligodendrocytes in situ. J Membr Biol189:201–212.
45.
Grissmer S, Lewis RS, Cahalan MD. 1992. Ca2+-activated K+ channels in human leukemic T cells. J Gen Physiol99:63–84.
46.
Hafler DA, Slavik JM, Anderson DE, O’Connor KC, De Jager P, Baecher-Allan C.2005. Multiple sclerosis. Immunol Rev204:208–231.
47.
Hansen A, Odendahl M, Reiter K, Jacobi A, Feist E, Scholze J, and others. 2002. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum46:2160–2171.
48.
Hellings N, Baree M, Verhoeven C, D’hooghe MB, Medaer R, Bernard CC, and others. 2001. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res63:290–302.
49.
Ishida Y, Chused TM. 1993. Lack of voltage sensitive potassium channels and generation of membrane potential by sodium potassium ATPase in murine T lymphocytes. J Immunol151:610–620.
50.
Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A, and others. 2002. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain125:538–550.
51.
Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. 1983. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci60:353–362.
52.
Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, and others. 2000. Induction of a non-encephalitogenic type 2 helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med6(10):1176–1182.
53.
Kernich CA. 2005. Current treatments for multiple sclerosis. Neurologist11:137–138.
54.
Khanna R, Roy L, Zhu X, Schlichter LC. 2001. K+ channels and the microglial respiratory burst. Am J Physiol Cell Physiol280:C796–C806.
55.
Klein U, Rajewsky K, Kuppers R.1998. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med188:1679–1689.
56.
Koni P, Khanna R, Chang M, Tang M, Kaczmarek L, Schlichter L, and others. 2003. Compensatory anion currents in Kv1.3 channel-deficient thymocytes. J Biol Chem278:39443–39451.
57.
Koo GC, Blake JT, Shah K, Staruch MJ, Dumont F, Wunderler D, and others. 1999. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol197:99–107.
58.
Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A, and others. 1997. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol158:5120–5128.
59.
Koschak A, Bugianesi RM, Mitterdorfer J, Kaczorowski GJ, Garcia ML, Knaus HG. 1998. Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatusvenom. J Biol Chem273:2639–2644.
60.
Kotecha S, Schlichter L.1999. A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. J Neurosci19:10680–10693.
61.
Lampeter EF, Homberg M, Quabeck K.1993. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet341:1243–1244.
62.
Lee SC, Levy DI, Deutsch C.1992. Diverse K+ channels in primary human T lymphocytes. J Gen Physiol99:771–793.
63.
Lewis RS. 2001. Calcium signaling mechanisms in T lymphocytes. Ann Rev Immunol19:497–521.
64.
Lewis RS, Cahalan MD. 1988. Subset-specific expression of potassium channels in developing murine T lymphocytes. Science239:771–775.
65.
Leyendeckers H, Voth E, Schichna H, Hunzelmann N, Banga P, Schmitz J.2002. Frequent detection of thyroid peroxidase-specific IgG+ memory B cells in blood of patients with autoimmune thyroid disease. Eur J Immunol32:3126–3132.
66.
Lin MS, Fu CL, Aoki V, Hans-Filho G, Rivitti EA, Moraes JR, and others. 2000. Desmoglein-1-specific T lymphocytes from patients with endemic pemphigus foliaceus (fogo selvagem). J Clin Invest105:207–213.
67.
Liu Q-H, Fleischmann BK, Hondowicz B, Maier CC, Turka LA, Yui K, and others. 2002. Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4+lymphocyte differentiation. J Exp Med196:897–909.
68.
Logsdon NJ, Kang J, Togo JA, Christian EP, Aiyar J.1997. A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J Biol Chem272:32723–32726.
69.
Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. 1998. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients: a marker of activated/memory T cells. J Clin Invest101:725–730.
70.
Mackenzie AB, Chirakkal H, North RA. 2003. Kv1.3 potassium channels in human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol285:L862–L868.
71.
Mahmoud F, Abul H, Haines D, Al-Saleh C, Khajeji M, Whaley K.2002. Decreased total numbers of peripheral blood lymphocytes with elevated percentages of CD4+CD45RO+ and CD4+CD25+ of T-helper cells in non-segmental vitiligo. J Dermatol29:68–73.
72.
Matteson DR, Deutsch C.1984. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature307:468–471.
73.
Miller D, Khan O, Sheremata W, Blumhardt L, Rice G, Libonati M, and others. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med348:15–23.
74.
Moretta A, Bottino C, Mingari M, Biassoni R, Moretta L.2002. What is a natural killer cell?Nat Immunol3:6–8.
75.
Mouhat S, Visan V, Ananthakrishnan S, Wulff H, Andreotti N, Grissmer S, and others. 2005. K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosusscorpion venom. Biochem J385:95–104.
76.
Neusch C, Rozengurt N, Jacobs R, Lester H, Kofuji P.2001. Kir4.1 potassium channel subunit is crucial for oligodendrocyte development and in vivo myelination. J Neurosci21:5429–5438.
77.
Ohta K, Norose K, Wang XC, Ito S, Yoshimura N.1997. Abnormal naive and memory T lymphocyte subsets in the peripheral blood of patients with uveitis. Curr Eye Res16:650–655.
78.
Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, for the Laquinimod in Relapsing MS Study Group. 2005. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology64:987–991.
79.
Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. 2003. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright,CD94bright,CD158negative phenotype. Rheumatology42:870–878.
80.
Raivich G, Banati R.2004. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Rev46:261–281.
81.
Reich E-P, Cui L, Yang L, Pugliese-Sivo C, Golovko A, Petro M, and others. 2005. Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur J Immunol35:1027–1036.
82.
Roep BO. 2003. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia46:305–321.
83.
Sallusto F, Geginat J, Lanzavecchia A.2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol22:745–763.
84.
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A.1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature401:708–712.
85.
Schilling T, Stock C, Schwab A, Eder C.2004. Functional importance of Ca2+-activated K+ channels for lysophophatidic acid-induced microglial migration. Eur J Neurosci19:1469–1474.
86.
Schlichter L, Sidell N, Hagiwara S.1986. Potassium channels mediate killing by human natural killer cells. Proc Natl Acad Sci U S A83:451–455.
87.
Schmidt K, Eulitz D, Veh R, Kettenmann H, Kirchhoff F.1999. Heterogeneous expression of voltage-gated potassium channels of the Shaker family (Kv1) in oligodendrocyte progenitors. Brain Res843:145–160.
88.
Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, and Wulff H.2005. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. Forthcoming.
89.
Schonrock LM, Kuhlmann T, Adler S, Bitsch A, Bruck W.1998. Identification of glial cell proliferation in early multiple sclerosis lesions. Neurophatol Appl Neurobiol24:320–330.
90.
Shi Y, Agematsu K, Ochs H, Sugane K.2003. Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol108:128–137.
91.
Sidell N, Schlichter L, Wright S, Hagiwara S, Golub S.1986. Potassium channels in human NK cells are involved in discrete stages of the killing process. J Immunol137:1650–1658.
92.
Stefoski D, Davis F, Faut M, Schauf C.1987. 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol21:71–77.
93.
Stefoski D, Davis F, Fitzsimmons W, Luskin S, Rush J, Parkhurst G.1991. 4-aminopyridine in multiple sclerosis: prolonged administration. Neurology41:1344–1348.
94.
Stewart-Akers A, Cunningham A, Wasko M, Morel P.2004. FcgR expression on NK cells influences disease severity in rheumatoid arthritis. Genes Immun5:521–529.
95.
Storey N, Gomez-Angelats M, Bortner C, Armstrong D, Cidlowski J.2003. Stimulation of Kv1.3 potassium channels by death receptors during apoptosis in Jurkat T lymphocytes. J Biol Chem278:33319–33326.
96.
Szabo I, Bock J, Jekle A, Soddemann M, Adams C, Lang F, and others. 2005. A novel potassium channel in lymphocyte mitochondria. J Biol Chem280:12790–12798.
97.
Szabo I, Gulbins E, Apfel H, Zhang X, Barth P, Busch AE, and others. 1996. Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation. J Biol Chem271:20465–20469.
98.
Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T.2004. The regulatory role of natural killer cells in multiple sclerosis. Brain127:1917–1927.
99.
Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, and others. 1999. The effect of anti-a4 integrin antibody on brain lesion activity in MS. Neurology53:466–472.
100.
Valverde P, Kawai T, Taubman M.2004. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J Bone Miner Res19:155–164.
101.
van Noort J.1999. Developing antigen-specific therapies in multiple sclerosis: a tale of Tantalus or Ulysses?Expert Opin Investig Drugs8:1537–1550.
102.
Vanderlugt C, Miller S.2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol2:85–95.
Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hansel W, and others. 2004. Kv1.3 blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol65:1364–1374.
105.
Verheugen JA, Vijverberg HP. 1995. Intracellular Ca2+ oscillations and membrane potential fluctuations in intact human T lymphocytes: role of K+ channels in Ca2+ signaling. Cell Calcium17:287–300.
106.
Vicente R, Escalada A, Coma M, Fuster G, Sanchez-Tillo E, Lopez-Iglesias C, and others. 2003. Differential voltage-dependent K+channel responses during proliferation and activation in macrophages. J Biol Chem278:46307–46320.
107.
Viglietta V, Kent SC, Orban T, Hafler DA. 2002. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest109:895–903.
108.
Villar LM, Sadaba MC, Roldan E, Masjuan J, Gonzalez-Porque P, Villarrubia N, and others. 2005. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest115:187–194.
109.
Vissers WHPM, Arndtz CHM, Muys L, Van Erp PEJ, De Jong EMG, Van De Kerhof PCM. 2002. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol150:852–859.
110.
Walz W, Bekar L.2001. Ion channels in cultured microglia. Microsc Res Tech54:26–33.
111.
Weinberg AD, Whitham R, Swain SL, Morrison WJ, Wyrick G, Hoy C, and others. 1992. Transforming growth factor-beta enhances the in vivo effector function and memory phenotype of antigen-specific T helper cells in experimental autoimmune encephalomyelitis. J Immunol148:2109–2117.
112.
Wolswijk G.2000. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain123:105–115.
113.
Wulff H, Beeton C, Chandy KG. 2003. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel6:640–647.
114.
Wulff H, Calabresi P, Allie R, Yun S, Pennington MW, Beeton C, and others. 2003. The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J Clin Invest111:1703–1713.
115.
Wulff H, Knaus H, Pennington M, Chandy KG. 2004. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol173:776–786.
116.
Ypey D, Clapham D.1984. Development of a delayed outward-rectifying K+ conductance in cultured mouse peritoneal macrophages. Proc Natl Acad Sci U S A81:3083–3087.
117.
Zhang X, Jiang S, Manczak M, Sugden B, Adamus G.2002. Phenotypes of T cells infiltrating the eyes in autoimmune anterior uveitis associated with EAE. Invest Ophthalmol Vis Sci43:1499–14508.
118.
Zhou W, Cayabyab FS, Pennefather PS, Schlichter LC, DeCoursey TE. 1998. HERG-like K+ channels in microglia. J Gen Physiol111:781–794.
